[ad_1]
SEATTLE, July 15, 2019 / PRNewswire / – Kineta, Inc., a clinical stage biotechnology company specializing in the development of innovative immunotherapies in oncology, neuroscience and biodefense, today announced the receipt of a grant. from the National Institute of Allergic and Infectious Diseases (NIAID) up to $ 5.8 million over 5 years to evaluate LHF-535 as a potential treatment for hemorrhagic arenaviruses, including Lbada, Junín and Machupo. LHF-535, Kineta's leading biodefactive active ingredient, is a new once-daily oral antiviral drug currently being evaluated in Phase 1 safety trials in healthy volunteers.
"This new collaboration with NIAID allows Kineta to extend the potential indications of LHF-535 to other arsenaviruses other than Lbada fever," said Kineta's general manager. Shawn Iadonato. "These life-threatening haemorrhagic viruses pose a significant threat to biological defense in the United States as well as a global health problem for patients in western regions. Africa and South America. "
The project, funded by NIAID through grant R01AI141102, aims to develop LHF-535 as a broad-spectrum antiviral drug for the treatment of multi-arenavirus haemorrhagic fever. In addition, Kineta will focus on defining how arenaviruses could develop drug resistance and develop an alternative formulation for intravenous dosing in patients. Since no drug is approved for the treatment of Lbada or any other arenavirus disease, LHF-535 could potentially significantly improve global health and serve as a medical countermeasure for biodefense.
Kineta, Inc. is a clinical-stage biotechnology company engaged in the development of disruptive life sciences technologies that address the unmet needs of patients. We leveraged our immunology expertise to advance a portfolio of experimental drugs in oncology, neuroscience and biodefense. We actively work with a wide range of private, government and industry partners to advance our innovative products. For more information on Kineta, visit our website, www.kinetabio.com, follow us on Twitter at @kinetabio, LinkedIn and Like us on facebook.com/KinetaBio.
Lbada fever is an acute viral disease that is known to be endemic West Africa. NIAID and the CDC have identified it as a Category A pathogen that poses the greatest risk to national security and public health. Lbada fever causes between 100,000 and 300,000 infections and is responsible for about 5,000 deaths a year West Africa. Mortality rates are particularly high among women in the third trimester of pregnancy, and fetal loss occurs in almost all infected pregnant women. There is a significant unmet medical need as there is currently no treatment or vaccine indicated to treat Lbada fever.
LHF-535 is a first-line antiviral treatment with potent activity against Lbada and other arenaviruses. It inhibits the entry of the virus into the target host cells and serves to suppress viral replication. It has demonstrated safety and effectiveness in preclinical models. In preclinical studies, LHF-535 has been shown to reduce viral titers and to ensure complete survival when administered therapeutically in Lbada-infected animals. LHF-535 is a daily once-a-day oral treatment being evaluated in unpublished phase 1 safety studies in humans. Kineta receives funding from the Wellcome Trust to advance LHF-535 Phase I safety studies and National Institutes of Health to investigate broader activity against arenaviruses.
NOTICE: This document contains certain forward-looking statements, including statements regarding Kineta's and Kineta Immuno-Oncology's plans for preclinical and clinical studies, regulatory filings, investor returns, and the expected effects of drugs at home. man. You are cautioned that forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in the business of Kineta and Kineta Immuno-Oncology that could materially affect the expected results, including, but not limited to progress in the development of drug development, clinical trials and approvals, developments in raw materials and personnel costs, and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta badumes no obligation to revise or update any forward-looking statement to reflect events or circumstances subsequent to the publication of this press release.
Media contact:
Jacques Bouchy
[email protected]
(206) 378-0400
SOURCE Kineta, Inc.
Source link
